Article Information
History
- May 19, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Katherine E. Mues, PhD, MPHa,*,
- Brenna Kirk, MSa,
- Deesha A. Patel, MSa,
- Alice Gelman, MSa,
- Scott Chavers, PhDb,
- Carla Talarico, PhDb,
- Daina B. Esposito, MPHb,
- David Martin, MD, MPHb,
- James Mansi, PhDb,
- Xing Chen, ScDb,
- Nicolle M. Gatto, PhD, MPHa and
- Nicolas Van de Velde, PhDb
- aAetion, Inc., 5 Pennsylvania Plaza, New York, NY 10001, USA
- bModerna, Inc., 200 Technology Square, Cambridge, MA 02139, USA
- ↵*Corresponding Author:
Katherine E. Mues, PhD, MPH Aetion, Inc. 5 Pennsylvania Plaza, New York, NY 10001, USA, Email: katie.mues{at}aetion.com, Telephone: 646-513-2200
Posted May 19, 2022.
Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults in the United States
